The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval.
Christina Bennett, MS
The findings further validate the initial 2015 findings that a five-fraction SBRT schedule is appropriate for patients with centrally located NSCLC.
Researchers evaluated whether breast cancer patients with hypothyroidism at diagnosis or who develop it later have an increased risk of recurrence or death.
The results of a new study add to the list of benefits seen with exercise among breast cancer survivors: reducing the risk of cardiovascular disease.
The phase II KEYNOTE-158 basket trial evaluated single-agent pembrolizumab in patients with previously treated advanced cervical cancer.
A review and meta-analysis in JAMA Oncology evaluated the incidence of treatment-related adverse events in patients receiving PD-1 or PD-L1 therapy.
The investigators tested the agent in patients who had solid tumors with NTRK gene fusions that had developed resistance to other TRK inhibitors.
A study looked at whether a lung cancer risk prediction model could identify patients at high risk for lung cancer who could receive less frequent low-dose CT screening.
Research presented at AACR 2019 evaluated autologous mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease.
A phase I trial evaluated the safety and efficacy of adding lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.